Tags

Type your tag names separated by a space and hit enter

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.
Antiviral Res. 2020 06; 178:104787.AR

Abstract

Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 able to effect ~5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans.

Authors+Show Affiliations

Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, At the Peter Doherty Institute for Infection and Immunity, Victoria, 3000, Australia.Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, At the Peter Doherty Institute for Infection and Immunity, Victoria, 3000, Australia.Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, At the Peter Doherty Institute for Infection and Immunity, Victoria, 3000, Australia.Biomedicine Discovery Institute, Monash University, Clayton, Vic, 3800, Australia.Biomedicine Discovery Institute, Monash University, Clayton, Vic, 3800, Australia. Electronic address: kylie.wagstaff@monash.edu.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

32251768

Citation

Caly, Leon, et al. "The FDA-approved Drug Ivermectin Inhibits the Replication of SARS-CoV-2 in Vitro." Antiviral Research, vol. 178, 2020, p. 104787.
Caly L, Druce JD, Catton MG, et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787.
Caly, L., Druce, J. D., Catton, M. G., Jans, D. A., & Wagstaff, K. M. (2020). The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research, 178, 104787. https://doi.org/10.1016/j.antiviral.2020.104787
Caly L, et al. The FDA-approved Drug Ivermectin Inhibits the Replication of SARS-CoV-2 in Vitro. Antiviral Res. 2020;178:104787. PubMed PMID: 32251768.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. AU - Caly,Leon, AU - Druce,Julian D, AU - Catton,Mike G, AU - Jans,David A, AU - Wagstaff,Kylie M, Y1 - 2020/04/03/ PY - 2020/03/18/received PY - 2020/03/27/revised PY - 2020/03/29/accepted PY - 2020/4/7/pubmed PY - 2020/7/7/medline PY - 2020/4/7/entrez SP - 104787 EP - 104787 JF - Antiviral research JO - Antiviral Res VL - 178 N2 - Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 able to effect ~5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans. SN - 1872-9096 UR - https://www.unboundmedicine.com/medline/citation/32251768/full_citation L2 - https://linkinghub.elsevier.com/retrieve/pii/S0166-3542(20)30201-1 DB - PRIME DP - Unbound Medicine ER -